Cristina
Alcacer

Neuroscientist. Fifteen years inside the parkinsonian striatum. Now teaching machines to read movement, so dopaminergic therapy can follow the patient.

PhD in Neuroscience · Université Paris VI Based at Cajal Neuroscience Center · CSIC
Striatal neurons firing in a freely moving
dyskinetic mouse · miniscope through a 1 mm lens

Current work · 2025 – now

Reading movement to personalize therapy

As a Momentum researcher at the Cajal Neuroscience Center (CSIC), I use AI to analyze behavior in mouse models of Parkinson's disease.

I study how different dopaminergic treatments and doses shape motor behavior in parkinsonian mice, using video, motion sensors and machine learning. The goal is a behavioral fingerprint for each therapy, built on movement features that also exist in wearable data from patients.

This work is moving toward the clinic. I am developing a neurotechnology concept, with a small interdisciplinary team, that could help make dopaminergic treatment more personalized and more responsive to each patient's day.

Measure

Capture motor behavior with video pose tracking and motion sensors, at sub-second resolution instead of coarse manual scores.

Decode & predict

Use machine learning to recognize the motor state produced by each dopaminergic treatment and dose, and to anticipate how it changes over time.

Translate

Turn these signatures into tools that help adjust treatment to the person.

Scientific journey

Four cities, one question

Why does the treatment that rescues movement in Parkinson's disease end up causing involuntary movements of its own, and what can we do about it?

2007 – 2011 Paris PhD, Université Pierre et Marie Curie, Paris VI
Institut du Fer-à-Moulin ↗
Girault lab

L-DOPA-induced dyskinesia is tied to over-active signaling in D1 striatal neurons.

I studied the molecular signaling behind L-DOPA-induced dyskinesia: the role of the Gαolf protein coupled to D1 receptors, and striatal gene expression in dyskinetic mice. I introduced stereotaxic surgery to the lab and established a mouse model of Parkinson's disease and dyskinesia, which the lab kept using after I left.

Key paper · first authorGαolf mutation allows parsing the role of cAMP-dependent and ERK-dependent signaling in L-DOPA-induced dyskinesia ↗Alcacer et al. · J Neurosci, 2012
2012 – 2015 Lund Postdoc, Lund University
Basal Ganglia Pathophysiology Unit
Cenci lab ↗

Dyskinesia can be turned up or down by targeting the two striatal pathways.

I set up chemogenetics (DREADDs) in the lab, at a time when few labs used it. Activating direct-pathway neurons made dyskinesia worse; activating indirect-pathway neurons reduced it. The result suggests that therapies acting on both pathways could treat Parkinson's disease and dyskinesia better than single-pathway approaches. The work was covered by Lund University, ScienceDaily and MedicalXpress.

Key paper · first & corresponding authorChemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy ↗Alcacer et al. · J Clin Invest, 2017
2016 – 2021 Lisbon Postdoc, Champalimaud Foundation (CF)
Champalimaud Research ↗
Neurobiology of Action · Costa lab ↗
(now at the Allen Institute, Seattle)

Each dyskinetic movement has its own hyperactive ensemble of striatal neurons.

Funded by a Marie Skłodowska-Curie grant, I brought Parkinson's models into a lab expert in movement control. I learned in vivo calcium imaging in freely moving mice, built a rotating platform with the Hardware Platform ↗ team from the CF, and used head-mounted inertial sensors, video and machine learning to detect dyskinesias automatically, at a resolution manual scoring cannot reach.

Key paper · co-first & corresponding authorAbnormal hyperactivity of specific striatal ensembles encodes distinct dyskinetic behaviors revealed by high-resolution clustering ↗Alcacer, Klaus et al. · Cell Reports, 2025
2022 – now Madrid University of Alcalá · IRYCIS ↗
María Zambrano fellow
Cajal Neuroscience Center ↗, CSIC · Momentum
Jercog lab ↗

Turning behavior into a readout of dopaminergic therapy.

With a María Zambrano talent-attraction grant I led an interdisciplinary project on how dopamine loss in the retina, a feature of Parkinson's disease, affects retinal circuits and visual function. I brought a parkinsonian model of retinal dopamine depletion into a retinal electrophysiology lab, co-supervised students, and taught Human Physiology to Pharmacy students at the UAH. At the Cajal Institute I set up fiber photometry and in vivo electrophysiology and supervised students as project manager.

Since 2025 I lead a Momentum project at the Cajal Neuroscience Center (CSIC), part of the programme “Develop your digital talent”, on AI-based behavioral analysis in mouse models of Parkinson's disease. It builds on the pipeline from my Cell Reports paper, which combined pose estimation, head-mounted motion sensors and unsupervised clustering to classify dyskinetic movements with sub-second precision.

I now apply this approach to a broader question: how different dopaminergic drugs, at different doses, shape motor behavior in parkinsonian and intact mice. The goal is an interpretable, data-driven framework that links pharmacology to behavior, built on movement features that also exist in wearable data from patients. The programme includes extensive training in AI (240 ECTS), which I am complementing with training in innovation and technology transfer.

Key paper · first & corresponding author · reviewAI-based mouse behavior analysis in pathology: a focus on movement disorders ↗Alcacer & Jercog · Neuroscience & Biobehavioral Reviews, 2026

Read the Cajal Neuroscience Center news story ↗ about this review.

Toolkit

From the bench to the model

Paris · since 2007

Disease models

  • Parkinson's disease & L-DOPA-induced dyskinesia mouse models
  • Stereotaxic surgery & viral vector delivery
  • Immunohistochemistry & confocal microscopy

Lund · Lisbon · Madrid

Manipulating & Recording circuits

  • ChemogeneticsGq- and Gs-DREADDs
  • Calcium imaging in freely moving miceminiscope, 1 mm GRIN lens
  • Fiber photometry
  • In vivo electrophysiology

Lisbon · Madrid · now

Reading behavior

  • Pose estimationDeepLabCut
  • Wearable motion sensorsinertial measurement units (IMUs)
  • Machine learning for behaviorunsupervised clustering · supervised classifiers (SVM, XGBoost)

Selected publications

Papers

h-index 10 · 1,700+ citations (Google Scholar) · 9 papers in Q1 journals

  1. 2026

    AI-based mouse behavior analysis in pathology: a focus on movement disorders

    Alcacer C, Jercog PE · Neuroscience & Biobehavioral Reviews · review · first & corresponding

  2. 2025

    Abnormal hyperactivity of specific striatal ensembles encodes distinct dyskinetic behaviors revealed by high-resolution clustering

    Alcacer C*, Klaus A*, Mendonça M, Abalde SF, Cenci MA, Costa RM · Cell Reports 44(7):115988 · co-first & corresponding

  3. 2017

    Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy

    Alcacer C, Andreoli L, Sebastianutto I, Jakobsson J, Fieblinger T, Cenci MA · J Clin Invest 127(2):720–734 · first & corresponding

  4. 2016

    Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

    Bastide MF, …, Alcacer C, …, Cenci MA, Bézard E · Prog Neurobiol 132:96–168 · co-first author

  5. 2015

    Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia

    Charbonnier-Beaupel F, Malerbi M, Alcacer C, … Corvol JC · J Neurosci 35(1):96–111 · co-first author

  6. 2014

    Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia

    Fieblinger T, Graves SM, Sebel LE, Alcacer C, … Surmeier DJ · Nat Commun 5:5316

  7. 2012

    Gα(olf) mutation allows parsing the role of cAMP-dependent and ERK-dependent signaling in L-DOPA-induced dyskinesia

    Alcacer C, Santini E, Valjent E, Gaven F, Girault JA, Hervé D · J Neurosci 32(17):5900–5910

Full list on ORCID.

Funding & recognition

Competitive grants

2025 – 2028Momentum ProgrammeBeneficiary

CSIC · NextGenerationEU. AI for animal behavior and neural activity analysis and integration.

2022 – 2024María Zambrano Talent AttractionPI

Talent-attraction grant to return to Spain. Striatal and visual motion processing in parkinsonian models.

2016 – 2019Marie Skłodowska-Curie International Career GrantPI

Swedish Research Council & European Commission. Striatal cells and the generation of akinesia and dyskinesia.

2016Marie Skłodowska-Curie Individual FellowshipPI · awarded, 96.4%

Declined in favor of the International Career Grant.

2019 – 2020ERC Proof of ConceptTeam member

Behavior phenotyping using inertial sensors (PI: R. Costa).

2014 – 2018Crafoord & Lars Hierta FoundationsPI

Swedish foundation grants on striatal cell types in Parkinson's disease.

Artwork by Cristina Alcacer: her silhouette, drawn as a pale grid, facing a striatal projection neuron with red, orange and yellow dendrites

Reflections

Four countries taught me resilience. Each lab asked me to learn something I didn't know yet.

In Paris I introduced a surgical model the lab didn't have. In Lund I set up chemogenetics and watched a hypothesis hold up, one of the most rewarding moments of my career. In Lisbon I joined a lab far stronger than me in programming and data analysis. It brought self-doubt at first, then motivation, and I left with new confidence and a deep respect for collaboration.

Those experiences point to what comes next: leading interdisciplinary projects where experimental neuroscience and AI meet, and carrying what we learn from movement toward tools that help patients.

Contact

Let's talk.

Open to collaborations in neuroscience, movement disorders and neurotechnology.

Emailcristina.alcacer@cajal.csic.es
Personal emailcristina.alcacer81@gmail.com
Elsewhere LinkedIn · ORCID
Portrait of Cristina Alcacer